You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 122 No. 11, November 1987 TABLE OF CONTENTS
  Archives
  •  Online Features
  PAPERS READ BEFORE THE ANNUAL MEETING OF THE SOCIETY OF SURGICAL ONCOLOGY, LONDON, APRIL 27 TO APRIL 30, 1987-PART I
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Therapy of Peritoneal Carcinomatosis of Human Colon Cancer Xenografts With Yttrium 90—Labeled Anti—Carcinoembryonic Antigen Antibody ZCE025

David M. Hyams, MD; Jose M. Esteban, MD; Charles P. Lollo, PhD; Barbara G. Beatty, PhD; J. David Beatty, MD

Arch Surg. 1987;122(11):1333-1337.


Abstract

• The present study was undertaken to determine whether an anti—carcinoembryonic antigen (CEA) monoclonal antibody (MAB), labeled with the potent beta emitter yttrium 90, could alter the growth of diffuse intraperitoneal carcinomatosis of colon cancer. Nude mice bearing the CEA-producing human tumor line LS174T received therapy with the anti-CEA MAB ZCE025 90Y. Animals were evaluated 12 days after therapy. Untreated animals had a mean (±SEM) tumor burden of 3.99±0.10 g, while animals treated with ZCE025 90Y had 0.29±0.04 g present. This decrease was significant compared with the 1.31 ±0.16 g of tumor present in animals treated with a 90Y-labeled nonspecific antibody 96.5c. The therapeutic effects seen with ZCE025 90Y suggest a potentially useful role for 90Y-labeled anti-CEA MABs in the treatment of gastrointestinal carcinomatosis.

(Arch Surg 1987;122:1333-1337)



Author Affiliations

From the Departments of General Oncologic Surgery (Drs Hyams, B. G. Beatty, and J. D. Beatty) and Anatomic Pathology (Dr Esteban), City of Hope National Medical Center, Duarte, Calif; and Hybritech Inc, San Diego (Dr Lollo).


Footnotes

Accepted for publication July 13, 1987.

Read before the Annual Meeting of the Society of Surgical Oncology, London, April 29, 1987.

Reprint requests to Department of General Oncologic Surgery, City of Hope National Medical Center, Duarte, CA 91010 (Dr J. D. Beatty).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Radiolabeling of Avidin with Very High Specific Activity for Internal Radiation Therapy of Intraperitoneally Disseminated Tumors
Mamede et al.
Clin. Cancer Res. 2003;9:3756-3762.
ABSTRACT | FULL TEXT  

Radioimmunotherapy of Human Colon Cancer in Nude Mice
Buras et al.
Arch Surg 1990;125:660-664.
ABSTRACT  

Prolongation of Survival of Nude Mice Bearing Human Colon Cancer: Treatment With Yttrium 90--Labeled Anti--Carcinoembryonic Antigen Antibody
Hyams et al.
Arch Surg 1989;124:175-179.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1987 American Medical Association. All Rights Reserved.